$233.18
0.30% day before yesterday
NYSE, Dec 27, 10:10 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Stock price

$233.18
-16.15 6.48% 1M
+41.60 21.71% 6M
+61.16 35.55% YTD
+60.20 34.80% 1Y
-28.89 11.02% 3Y
+76.98 49.28% 5Y
+176.28 309.81% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.70 0.30%
ISIN
US7611521078
Symbol
RMD
Sector

Key metrics

Market capitalization $34.23b
Enterprise Value $34.65b
P/E (TTM) P/E ratio 30.91
EV/FCF (TTM) EV/FCF 25.61
EV/Sales (TTM) EV/Sales 7.21
P/S ratio (TTM) P/S ratio 7.12
P/B ratio (TTM) P/B ratio 6.59
Dividend yield 0.82%
Last dividend (FY24) $1.92
Revenue growth (TTM) Revenue growth 9.88%
Revenue (TTM) Revenue $4.81b
EBIT (operating result TTM) EBIT $1.48b
Free Cash Flow (TTM) Free Cash Flow $1.35b
Cash position $426.36m
EPS (TTM) EPS $7.54
P/E forward 25.91
P/S forward 6.68
EV/Sales forward 6.77
Short interest 5.91%
Show more

Is ResMed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ResMed Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a ResMed forecast:

16x Buy
64%
8x Hold
32%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a ResMed forecast:

Buy
64%
Hold
32%
Sell
4%

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,807 4,807
10% 10%
100%
- Direct Costs 2,080 2,080
4% 4%
43%
2,727 2,727
15% 15%
57%
- Selling and Administrative Expenses 717 717
3% 3%
15%
- Research and Development Expense 311 311
4% 4%
6%
1,699 1,699
24% 24%
35%
- Depreciation and Amortization 216 216
5% 5%
5%
EBIT (Operating Income) EBIT 1,482 1,482
27% 27%
31%
Net Profit 1,113 1,113
23% 23%
23%

In millions USD.

Don't miss a Thing! We will send you all news about ResMed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ResMed Stock News

Negative
Investopedia
5 days ago
Shares of ResMed (RMD) and Inspire Medical Systems (INSP) fell Monday as the companies behind products to treat sleep apnea faced a new threat from weight-loss drugs.
Positive
Schaeffers Research
6 days ago
Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- the first such treatment in the country.
Neutral
GlobeNewsWire
25 days ago
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Canada Sleep Apnea Devices Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ResearchAndMarkets.com's offering. Canada Sleep Apnea Devices Market was valued at USD 338.54 Million in 2023 and is expected to reach USD 465.53 Million by 2029 with a CAGR of 5.41%
More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office United States
CEO Mick Farrell
Employees 9,980
Founded 1989
Website www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today